Theseus Pharmaceuticals Crecimiento futuro

Future controles de criterios 0/6

Se prevé que los beneficios de Theseus Pharmaceuticals disminuyan en un 6.3% al año. Se prevé que el BPA aumente en un 14.2% al año.

Información clave

-6.3%

Tasa de crecimiento de los beneficios

14.2%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Pharmaceuticals	23.8%
Tasa de crecimiento de los ingresos	n/a
Rentabilidad financiera futura	n/a
Cobertura de analistas	Low
Última actualización	12 Feb 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Theseus Pharmaceuticals: Biotech Buyout Remains Attractive At $4.06 Because Of 2-Part CVR

Feb 01

Theseus Pharmaceuticals (NASDAQ:THRX) Is In A Good Position To Deliver On Growth Plans

Aug 18

Companies Like Theseus Pharmaceuticals (NASDAQ:THRX) Are In A Position To Invest In Growth

May 05

Companies Like Theseus Pharmaceuticals (NASDAQ:THRX) Are In A Position To Invest In Growth

Dec 07

Theseus Pharmaceuticals GAAP EPS of -$0.30 in-line

Aug 11

Here's Why We're Not Too Worried About Theseus Pharmaceuticals' (NASDAQ:THRX) Cash Burn Situation

Apr 22

Previsiones de crecimiento de beneficios e ingresos

NasdaqGS:THRX - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	N/A	-66	N/A	-55	1
12/31/2025	N/A	-53	N/A	-42	1
12/31/2024	N/A	-49	N/A	-39	1
12/31/2023	N/A	-56	N/A	-48	1
9/30/2023	N/A	-57	-50	-50	N/A
6/30/2023	N/A	-58	-46	-46	N/A
3/31/2023	N/A	-55	-44	-44	N/A
12/31/2022	N/A	-51	-33	-33	N/A
9/30/2022	N/A	-46	-33	-33	N/A
6/30/2022	N/A	-38	-31	-31	N/A
3/31/2022	N/A	-33	-30	-30	N/A
12/31/2021	N/A	-27	-27	-27	N/A
9/30/2021	N/A	-22	-19	-19	N/A
6/30/2021	N/A	-16	-14	-14	N/A
3/31/2021	N/A	-13	-9	-9	N/A
12/31/2020	N/A	-12	-5	-5	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Se prevé que THRX siga sin ser rentable en los próximos 3 años.

Beneficios vs. Mercado: Se prevé que THRX siga sin ser rentable en los próximos 3 años.

Beneficios de alto crecimiento: Se prevé que THRX siga sin ser rentable en los próximos 3 años.

Ingresos vs. Mercado: No hay datos suficientes para determinar si se prevé que los ingresos de THRX crezcan más rápidamente que el mercado de US.

Ingresos de alto crecimiento: Se prevé que THRX no tenga ingresos el año que viene.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de THRX se prevé que sea elevada dentro de 3 años.

Theseus Pharmaceuticals Crecimiento futuro

Future controles de criterios 0/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Price target decreased by 70% to US$6.75

Recent updates

Theseus Pharmaceuticals Files Form 15

Theseus Pharmaceuticals, Inc.(NasdaqGS:THRX) dropped from NASDAQ Composite Index

Concentra Biosciences, LLC completed the acquisition of Theseus Pharmaceuticals, Inc. (NasdaqGS:THRX).

Theseus Pharmaceuticals' Common Stock to be Cease Trading on Nasdaq at the Opening of Trading on February 14, 2024, and Intends Promptly to Cause to be Delisted from Nasdaq

Theseus Pharmaceuticals: Biotech Buyout Remains Attractive At $4.06 Because Of 2-Part CVR

Theseus Pharmaceuticals, Inc. Announces Employment Termination of Timothy P. Clackson as Chief Executive Officer, Effective December 7, 2023

Theseus Pharmaceuticals, Inc. announced delayed 10-Q filing

Key Executive exercised options to buy US$555k worth of stock.

New minor risk - Market cap size

Theseus Pharmaceuticals (NASDAQ:THRX) Is In A Good Position To Deliver On Growth Plans

New major risk - Share price stability

Price target decreased by 70% to US$6.75

Theseus Pharmaceuticals to Discontinue Enrollment in Phase 1/2 Study and Terminate Development of The-630 in Patients with Gist

Theseus Pharmaceuticals Reports Initial Dose Escalation Data from Ongoing Phase 1/2 Trial of THE-630 in Patients with Advanced GIST

Companies Like Theseus Pharmaceuticals (NASDAQ:THRX) Are In A Position To Invest In Growth

Theseus Pharmaceuticals Highlights Key Anticipated 2023 Milestones and Announces BCR-ABL as Target for Third Development Program

Companies Like Theseus Pharmaceuticals (NASDAQ:THRX) Are In A Position To Invest In Growth

Less than half of directors are independent

Theseus Pharmaceuticals Presents Preclinical Data Characterizing The-349, Its Fourth-Generation EGFR Inhibitor in Development for NSCLC, at the 34th EORTC-NCI-AACR Symposium

Theseus Pharmaceuticals, Inc. Appoints Steven Stein to Board of Directors

Theseus Pharmaceuticals, Inc. Nominates The-349, A Fourth-Generation EGFR Inhibitor Development Candidate in Non-Small Cell Lung Cancer

Theseus Pharmaceuticals GAAP EPS of -$0.30 in-line

Theseus Pharmaceuticals, Inc.(NasdaqGS:THRX) dropped from Russell 2000 Growth Index

Theseus Pharmaceuticals Appoints Don Hayden to Board of Directors

Less than half of directors are independent

Theseus Pharmaceuticals, Inc., Annual General Meeting, Jun 10, 2022

Here's Why We're Not Too Worried About Theseus Pharmaceuticals' (NASDAQ:THRX) Cash Burn Situation

Theseus Pharmaceuticals, Inc. Announces Preclinical Data Characterizing Next-Generation Epidermal Growth Factor Receptor (Egfr) Inhibitors At the 2022 American Association for Cancer Research (Aacr) Annual Meeting

Theseus Pharmaceuticals Announces First Patient Treated with The-630 in Phase 1/2 Study in Patients with Advanced Gastrointestinal Stromal Tumors

Less than half of directors are independent

Previsiones de crecimiento de beneficios e ingresos

Previsiones de crecimiento futuro de los analistas

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

Descubre empresas en crecimiento